An update on the molecular genetics of hepatocellular carcinoma.

PubWeight™: 1.15‹?› | Rank: Top 10%

🔗 View Article (PMID 15085488)

Published in Semin Liver Dis on February 01, 2004


Arief Suriawinata1, Ruliang Xu

Author Affiliations

1: Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.

Articles citing this

Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis (2010) 2.46

Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol (2005) 1.87

Targeted therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2009) 1.27

Thyroid hormone receptors mutated in liver cancer function as distorted antimorphs. Oncogene (2006) 1.26

LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol (2009) 1.07

Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. Hepatology (2011) 1.07

Involvement of c-myc-regulated genes in hepatocellular carcinoma related to genotype-C hepatitis B virus. J Cancer Res Clin Oncol (2006) 0.89

LAPTM4B allele *2 is a marker of poor prognosis following hepatic tumor resection for hepatocellular carcinoma. PLoS One (2012) 0.87

Genetic alterations of hepatocellular carcinoma by random amplified polymorphic DNA analysis and cloning sequencing of tumor differential DNA fragment. World J Gastroenterol (2005) 0.85

Deficiency of G1 regulators P53, P21Cip1 and/or pRb decreases hepatocyte sensitivity to TGFbeta cell cycle arrest. BMC Cancer (2007) 0.85

Evolving therapies in the treatment of hepatocellular carcinoma. Biologics (2008) 0.83

Gene expression analysis in HBV transgenic mouse liver: a model to study early events related to hepatocarcinogenesis. Mol Med (2006) 0.83

Wilson disease and hepatocellular carcinoma. Gastroenterol Hepatol (N Y) (2008) 0.83

Generation of functional CD8+ T cells by human dendritic cells expressing glypican-3 epitopes. J Exp Clin Cancer Res (2010) 0.81

Reduced expression of C/EBP alpha protein in hepatocellular carcinoma is associated with advanced tumor stage and shortened patient survival. J Cancer Res Clin Oncol (2008) 0.80

A survey on herbal management of hepatocellular carcinoma. World J Hepatol (2011) 0.80

High leukocyte mtDNA content contributes to poor prognosis through ROS-mediated immunosuppression in hepatocellular carcinoma patients. Oncotarget (2016) 0.78

Rare allelic imbalances, but no mutations of the PRDX1 gene in human hepatocellular carcinomas. J Clin Pathol (2005) 0.78

Reduced expression of ASS is closely related to clinicopathological features and post-resectional survival of hepatocellular carcinoma. Oncol Lett (2010) 0.78

Expression liver-directed genes by employing synthetic transcriptional control units. World J Gastroenterol (2005) 0.77

miR-214/199a/199a* cluster levels predict poor survival in hepatocellular carcinoma through interference with cell-cycle regulators. Oncotarget (2016) 0.77

Association of MDR1 gene polymorphisms with the risk of hepatocellular carcinoma in the Chinese Han population. Braz J Med Biol Res (2013) 0.75

Association study of single nucleotide polymorphisms in XRCC1 gene with risk of hepatocellular carcinoma in Chinese Han population. Biomed Res Int (2013) 0.75

DLEC1 Expression Is Modulated by Epigenetic Modifications in Hepatocelluar Carcinoma Cells: Role of HBx Genotypes. Cancers (Basel) (2010) 0.75

Prescription frequency and patterns of Chinese herbal medicine for liver cancer patients in Taiwan: a cross-sectional analysis of the National Health Insurance Research Database. BMC Complement Altern Med (2017) 0.75

Articles by these authors

Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol (2005) 4.28

Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology (2007) 3.99

Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology (2006) 2.78

The myeloid differentiation factor 88 (MyD88) is required for CD4+ T cell effector function in a murine model of inflammatory bowel disease. J Immunol (2008) 1.75

Comparative usage of herpesvirus entry mediator A and nectin-1 by laboratory strains and clinical isolates of herpes simplex virus. Virology (2004) 1.73

GPR15-mediated homing controls immune homeostasis in the large intestine mucosa. Science (2013) 1.58

Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors. Inflamm Bowel Dis (2009) 1.53

De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature. Dig Dis Sci (2006) 1.45

A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am J Physiol Gastrointest Liver Physiol (2009) 1.39

Toll-like receptor 4 differentially regulates epidermal growth factor-related growth factors in response to intestinal mucosal injury. Lab Invest (2010) 1.23

Molecular genetics of hepatocellular neoplasia. Am J Transl Res (2010) 1.16

Molecular classification of soft tissue sarcomas and its clinical applications. Int J Clin Exp Pathol (2010) 1.15

Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost (2004) 1.12

Histologic characteristics of pancreatic intraepithelial neoplasia associated with different pancreatic lesions. Hum Pathol (2010) 0.99

Copy number and gene expression differences between African American and Caucasian American prostate cancer. J Transl Med (2010) 0.99

Benign hybrid perineurioma-schwannoma in the colon. A case report. Ann Diagn Pathol (2006) 0.97

Microcarcinoids in large intestinal adenomas. Am J Surg Pathol (2006) 0.95

Co-expression of XIAP and cyclin D1 complex correlates with a poor prognosis in patients with hepatocellular carcinoma. Am J Pathol (2012) 0.93

The role of prostaglandin E2 (PGE 2) in toll-like receptor 4 (TLR4)-mediated colitis-associated neoplasia. BMC Gastroenterol (2010) 0.93

Androgen receptor coactivator p44/Mep50 in breast cancer growth and invasion. J Cell Mol Med (2010) 0.90

Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression. J Clin Invest (2013) 0.88

Expression and function of androgen receptor coactivator p44/Mep50/WDR77 in ovarian cancer. PLoS One (2011) 0.87

Liver transplant for mixed capillary-cavernous hemangioma masquerading as hepatocellular carcinoma in a patient with hepatocellular carcinoma. Exp Clin Transplant (2011) 0.86

Inverse relationship between cirrhosis and massive tumours in hepatocellular carcinoma. HPB (Oxford) (2012) 0.83

Budd-Chiari syndrome in sarcoidosis involving liver. Liver Int (2008) 0.82

Urethral adenocarcinoma associated with intestinal-type metaplasia, case report and literature review. Int J Clin Exp Pathol (2013) 0.81

KRAS mutations are associated with specific morphologic features in colon cancer. J Clin Gastroenterol (2013) 0.78

Distinct function of androgen receptor coactivator ARA70α and ARA70β in mammary gland development, and in breast cancer. Breast Cancer Res Treat (2010) 0.77

Pancreatic carcinoma with multilineage (acinar, neuroendocrine, and ductal) differentiation. Int J Clin Exp Pathol (2009) 0.77

Functional domains of androgen receptor coactivator p44/Mep50/WDR77and its interaction with Smad1. PLoS One (2013) 0.77

Segmentation of microscopic images of small intestinal glands with directional 2-D filters. Anal Quant Cytol Histol (2005) 0.77

Race and the molecular origins of breast cancer in Chinese women: breast cancer in Chinese women. Ann Surg Oncol (2012) 0.76

A 48-year-old obese man with a 3 cm liver lesion and a history of hemochromatosis and lymphoma. Semin Liver Dis (2004) 0.75

Is metastatic potential of breast cancer inherent or acquired? Lab Invest (2004) 0.75